Lymphoma, B-Cell: all 1,415 studies
Page 2 of 15. Open to participants first (328), then studies with results posted, then the rest; newest registration first within each.
- Study of Pomalidomide Combination with Rituximab and Anti-PD-1 Antibody （PPR） in Third or Later Line Therapy of DLBCLRecruitingNCT06832228Not applicable
- Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell LymphomaRecruitingNCT06830031Phase 1
- A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06822868Phase 1
- A Study of XS-04 in Patients With Relapsed or Refractory Hematologic MalignanciesRecruitingNCT06820268Phase 1
- Immunotherapy in LymphomaRecruitingNCT06796517
- Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell LymphomasRecruitingNCT06792734Phase 1
- An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient ProgramRecruitingNCT06782789
- AZA Combined with R-GemOx for Elderly DLBCL PatientsNot yet recruitingNCT06778902Phase 2
- CHiR Therapy for Elderly DLBCL Intolerant to ChemoRecruitingNCT06764017Phase 2
- Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic MalignanciesRecruitingNCT06758713Phase 1
- Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients with DLBCL Intolerant to ChemotherapyRecruitingNCT06758037Phase 2
- PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell LymphomaRecruitingNCT06755775
- Dynamic CtDNA-guided Targeted Therapy in DLBCLNot yet recruitingNCT06748521Phase 2
- A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)RecruitingNCT06742996Phase 3
- Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBLRecruitingNCT06742502Phase 2
- A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06734871Phase 1
- A Study of JMT601 in Participants With Relapsed or Refractory CD20-positive B-cell Non-Hodgkin LymphomaRecruitingNCT06725524Phase 1
- Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell LymphomaRecruitingNCT06723457Phase 2
- An Extension Study to Evaluate the Safety and Efficacy of an Anti-CD19 CAR-T Product in Patients with B-cell Lymphoproliferative DisordersNot yet recruitingNCT06721598
- Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical ResearchRecruitingNCT06716164Early Phase 1
- Clinical Study of Cord Blood-derived IL-10/IL-15 CD19-CAR NK in the Treatment of Refractory/Relapsed B-cell NHLRecruitingNCT06707259Phase 1
- To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)RecruitingNCT06698484Phase 2
- An Early Clinical Study Evaluating the Safety and Efficacy of AcNK-Sup003 Cell Injection in the Treatment of Relapsed or Refractory B-cell Non-Hodgkin's LymphomaRecruitingNCT06693973Early Phase 1
- ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCLRecruitingNCT06693830Not applicable
- A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and Prednisone for the Primary Treatment of Elderly Patients with Newly Diagnosed Diffuse Large B-cell LymphomaRecruitingNCT06683885Phase 1/2
- Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial RemissionNot yet recruitingNCT06669143Phase 2
- The Effectiveness and Safety of Glofitamab in Real-World Clinical Practice Among Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter StudyNot yet recruitingNCT06656234
- Mechanism Investigation of R-CHOP Regimen or Tucidinostat Plus R-CHOP (CR-CHOP) Regimen in the Treatment of BCL2/MYC Protein Double Expressor LymphomaNot yet recruitingNCT06652152
- Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC PositiveNot yet recruitingNCT06652139Phase 2
- ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCTNot yet recruitingNCT06646666Phase 2
- A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesRecruitingNCT06634589Phase 1/2
- One Trial to Evaluate the Safety, Tolerability and Efficacy of JCXH-213 in Patients With r/r B-NHLRecruitingNCT06618313Not applicable
- Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell LymphomaRecruitingNCT06609304Phase 4
- A Real-World Study on Extranodal LymphomaNot yet recruitingNCT06573099
- CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic FactorsNot yet recruitingNCT06567366Phase 2
- A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell LymphomaRecruitingNCT06566586Phase 2
- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012RecruitingNCT06565689Phase 1
- A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesRecruitingNCT06564038Phase 1/2
- A Study of Zanubrutinib in Combination With Polatuzumab Vedotin, Bendamustine and Rituximab in the Treatment of Relapsed/Refractory Diffuse Large B-cell LymphomaRecruitingNCT06554600Phase 2
- SynKIR-310 for Relapsed/Refractory B-NHLRecruitingNCT06544265Phase 1
- Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical StudyRecruitingNCT06534762Phase 2
- Polatuzumab, Rituximab and Orelabrutinib Combination Regimen (PRO) in the Treatment of Elderly Frail Patients with Treatment-naive Non-GCB DLBCLRecruitingNCT06530511Phase 2
- A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell MalignanciesRecruitingNCT06528301Phase 1
- Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHLRecruitingNCT06526793Phase 2
- The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaRecruitingNCT06522555Phase 3
- An Open-label, Single-arm Study of JWCAR201 in the Treatment of Relapsed or Refractory Diffuse Large B-cell LymphomaRecruitingNCT06517004Phase 1
- A Study Comparing the Efficacy and Safety of Pola-RCHP-X Versus RCHOP-X and Pola-RCHP in Previously Untreated Patients With DLBCLNot yet recruitingNCT06516978Phase 2
- Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell NeoplasmsRecruitingNCT06508931Phase 2
- Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene TherapiesRecruitingNCT06508775Not applicable
- The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and RadiotherapyRecruitingNCT06503276Phase 2
- Zanubrutinib and Lenalidomide as Maintenance Therapy in DLBCLRecruitingNCT06503263Phase 2
- A Study of Efficacy and Safety of Glofitamab in Combination With Salvage Therapy in a Real-world Setting in Chinese Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.RecruitingNCT06497452
- Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCLRecruitingNCT06489808Phase 2
- Early Palliative Care for Patients With Multiple Myeloma and Aggressive LymphomaRecruitingNCT06485076Not applicable
- A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHLRecruitingNCT06484920Phase 2
- CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell LymphomaRecruitingNCT06479356Phase 2
- L218CAR19 in Patients With Relapsed/Refractory B-cell LymphomaRecruitingNCT06478381Phase 1
- Sequential Treatment of CD19 CARNK and 7x19 CAR-T in R/R B Cell LymphomaRecruitingNCT06464861Phase 1
- Ga-68-CXCR4 PET/CT in Indolent B-cell LymphomaRecruitingNCT06461182Phase 2
- A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed or Refractory B Cell Non-Hodgkin Lymphoma(NHL)RecruitingNCT06446128Early Phase 1
- CD19/CD22 CAR-T Cells in Adults With R/R ALL or NHLRecruitingNCT06445803Phase 1
- Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell LymphomaRecruitingNCT06445517Phase 1
- Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLNot yet recruitingNCT06441097Phase 2
- Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell LymphomaRecruitingNCT06415708Phase 2
- MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell LymphomaRecruitingNCT06414148Phase 2
- A Prospective Study: Sintilimab and R-CHOP in PMBCL TreatmentNot yet recruitingNCT06412068Phase 2
- Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06395870Phase 1
- A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.RecruitingNCT06393738Phase 1
- A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Relapsed/ Refractory B-Cell Non-Hodgkin LymphomaRecruitingNCT06392477Phase 1
- Treatment of Relapsed or Refractory B-cell Lymphoma With Chimeric Antigen Receptor (CAR) T-cell Therapy Produced by a New TechnologyRecruitingNCT06378190Phase 1/2
- CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic FactorsRecruitingNCT06365671Phase 2
- Early Assessment of Cardiac Function After Treatment With CAR-T CellsRecruitingNCT06350994
- Rituximab and Zanubrutinib in Patients With Indolent B-cell LymphomasRecruitingNCT06350318Phase 2
- CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHLRecruitingNCT06346912Early Phase 1
- T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)RecruitingNCT06343311Phase 1/2
- Italian Observational Study on CAR-T Therapy for LymphomaRecruitingNCT06339255
- Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHLRecruitingNCT06321289Phase 1/2
- A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin LymphomaNot yet recruitingNCT06318884Phase 1
- A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHLNot yet recruitingNCT06314828Phase 1
- A Study of LUCAR-20SP in Subjects With Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06313957Phase 1
- Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPIRecruitingNCT06290817Phase 2
- Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCLRecruitingNCT06287398Phase 2
- Prospective Observational Study of Diffuse Large-cell B LymphomaRecruitingNCT06241729
- Epcoritamab Compared to Observation for Treating B-cell Lymphoma Patients Not in Complete Remission After CD19-directed CAR-T TherapyRecruitingNCT06238648Phase 2
- Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).RecruitingNCT06213636Phase 1/2
- A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell LymphomaRecruitingNCT06213311Phase 2
- CLIC-2201 for the Treatment of Relapsed/Refractory B Cell MalignanciesRecruitingNCT06208735Phase 1
- B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic MalignanciesRecruitingNCT06191887Phase 1
- A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)RecruitingNCT06189391Phase 1
- CD30 Imaging in Diffuse Large B-cell LymphomaNot yet recruitingNCT06186986Phase 3
- Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell LymphomaRecruitingNCT06180174Phase 1
- A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)RecruitingNCT06173518Phase 1
- Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT06164327Phase 1
- Characterization and Clinical Impact of the Gut Microbiota in LymphomaRecruitingNCT06161896
- The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)RecruitingNCT06160362Not applicable
- AZA Combined With RCHOP in P53-mutated DLBCL.RecruitingNCT06158399Phase 2
- Lenalidomide Combined With G-CHOP in the Treatment of Newly Diagnosed DLBCL With FLRecruitingNCT06151080Phase 2
- Relmacabtagene Autoleucel in Hematologic MalignanciesNot yet recruitingNCT06142188
- Relmacabtagene Autoleucel in Patients With LBCLRecruitingNCT06142175
- Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a SolutionRecruitingNCT06131801